Shire (SHPG) Rating Increased to Hold at ValuEngine
ValuEngine upgraded shares of Shire (NASDAQ:SHPG) from a sell rating to a hold rating in a research report report published on Friday morning.
A number of other equities analysts have also issued reports on SHPG. Berenberg Bank lowered shares of Shire from a buy rating to a hold rating in a research report on Friday, September 7th. BidaskClub upgraded shares of Shire from a sell rating to a hold rating in a research report on Tuesday, July 3rd. Cantor Fitzgerald set a $222.00 target price on shares of Shire and gave the stock a buy rating in a research report on Tuesday, July 31st. Evercore ISI lowered shares of Shire from an outperform rating to a market perform rating and set a $196.00 target price on the stock. in a research report on Tuesday, September 4th. Finally, Sanford C. Bernstein lowered shares of Shire from an outperform rating to a market perform rating in a research report on Tuesday, September 4th. Nine investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The stock currently has an average rating of Buy and an average target price of $200.75.
Shares of SHPG opened at $178.38 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.02 and a current ratio of 1.55. The company has a market cap of $54.22 billion, a PE ratio of 11.77, a price-to-earnings-growth ratio of 1.58 and a beta of 1.22. Shire has a 12-month low of $123.73 and a 12-month high of $181.41.
The company also recently disclosed a dividend, which will be paid on Friday, October 19th. Investors of record on Friday, September 7th will be given a $0.168 dividend. The ex-dividend date is Thursday, September 6th. Shire’s dividend payout ratio (DPR) is 2.24%.
A number of large investors have recently bought and sold shares of SHPG. PointState Capital LP grew its position in Shire by 4,642.0% in the 2nd quarter. PointState Capital LP now owns 711,296 shares of the biopharmaceutical company’s stock valued at $120,067,000 after buying an additional 696,296 shares during the last quarter. LMR Partners LLP purchased a new position in Shire in the 2nd quarter valued at $55,664,000. SG Americas Securities LLC grew its position in Shire by 1,634.4% in the 2nd quarter. SG Americas Securities LLC now owns 193,547 shares of the biopharmaceutical company’s stock valued at $32,671,000 after buying an additional 182,388 shares during the last quarter. Prosight Management LP acquired a new stake in Shire in the first quarter valued at $21,828,000. Finally, Delek Group Ltd. lifted its holdings in Shire by 101.0% in the first quarter. Delek Group Ltd. now owns 252,750 shares of the biopharmaceutical company’s stock valued at $37,797,000 after acquiring an additional 127,000 shares during the period. Hedge funds and other institutional investors own 17.85% of the company’s stock.
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
See Also: How Do Tariffs Affect Trade Balances?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.